Get started
Author

Maria Cristina Sauerland

Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
2013 · Hubert Serve, Utz Krug, et al. · Journal of Clinical Oncology · 313
PDF
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes
2010 · Utz Krug, Christoph Röllig, et al. · The Lancet · 304
Morphologic Dysplasia in De Novo Acute Myeloid Leukemia (AML) Is Related to Unfavorable Cytogenetics but Has No Independent Prognostic Relevance Under the Conditions of Intensive Induction Therapy: Results of a Multiparameter Analysis From the German AML Cooperative Group Studies
2003 · Torsten Haferlach, Claudia Schoch, et al. · Journal of Clinical Oncology · 195
Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
2020 · Tobias Herold, Maja Rothenberg-Thurley, et al. · Leukemia · 192
PDF
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients
2001 · Claudia Schoch, Torsten Haferlach, et al. · British Journal of Haematology · 178
PDF
6-Thioguanine, Cytarabine, and Daunorubicin (TAD) and High-Dose Cytarabine and Mitoxantrone (HAM) for Induction, TAD for Consolidation, and Either Prolonged Maintenance by Reduced Monthly TAD or TAD-HAM-TAD and One Course of Intensive Consolidation by Sequential HAM in Adult Patients at All Ages With De Novo Acute Myeloid Leukemia (AML): A Randomized Trial of the German AML Cooperative Group
2003 · Thomas Büchner, Wolfgang Hiddemann, et al. · Journal of Clinical Oncology · 164
GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia
2012 · Philipp A. Greif, Annika Dufour, et al. · Blood · 149
A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia
2017 · Tobias Herold, Vindi Jurinovic, et al. · Haematologica · 139
Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm—Combined Prospective Analysis by the German AML Intergroup
2012 · Thomas Büchner, Richard F. Schlenk, et al. · Journal of Clinical Oncology · 134
Significance of age in acute myeloid leukemia patients younger than 30 years
2007 · Ursula Creutzig, Thomas Büchner, et al. · Cancer · 115
PDF
Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Cytogenetically Normal Acute Myeloid Leukemia
2014 · Friederike Pastore, Annika Dufour, et al. · Journal of Clinical Oncology · 111
PDF
Allogeneic Transplantation Versus Chemotherapy as Postremission Therapy for Acute Myeloid Leukemia: A Prospective Matched Pairs Analysis
2013 · Matthias Stelljes, Utz Krug, et al. · Journal of Clinical Oncology · 106
PDF
Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis
2014 · Tobias Herold, Klaus H. Metzeler, et al. · Blood · 102
Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML)
2011 · Friederike Schneider, Eva Hoster, et al. · Annals of Hematology · 83
The clinical mutatome of core binding factor leukemia
2020 · Sabrina Opatz, Stefanos A. Bamopoulos, et al. · Leukemia · 77
PDF
The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis
1997 · Claudia Schoch, Detlef Haase, et al. · British Journal of Haematology · 76
PDF
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet
2015 · E Lengfelder, F Lo-Coco, et al. · Leukemia · 75
High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia
2012 · Klaus H. Metzeler, Bernhard Heilmeier, et al. · Blood · 72
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
2005 · Matthias Stelljes, Martin Bornhauser, et al. · Blood · 72
Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia
2020 · Stefanos A. Bamopoulos, Aarif M. N. Batcha, et al. · Leukemia · 71
PDF
ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation
2016 · Luise Hartmann, Sayantanee Dutta, et al. · Nature Communications · 60
PDF
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial
2011 · M. Stelljes, D. W. Beelen, et al. · Haematologica · 58
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)
2009 · Friederike Schneider, Eva Hoster, et al. · Blood · 58
Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia
2013 · Sabrina Opatz, Harald Polzer, et al. · Blood · 55
A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
2004 · Torsten Haferlach, Wolfgang Kern, et al. · PubMed · 52
Works count: 101
Citation count: 3,592
H-index: 33
I10-index: 46
Year
Topic
Type